MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the ...
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera ...
clinicaltrialsarena5h
Moderna doses first subject in Phase III trial of mRNA norovirus vaccine in US
Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403.
PipelineReview.com5h
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
CAMBRIDGE, MA, USA I September 30, 2024 I Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 ...